GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (GREY:KIADF) » Definitions » Price-to-Owner-Earnings

Kiadis Pharma NV (Kiadis Pharma NV) Price-to-Owner-Earnings : (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Kiadis Pharma NV Price-to-Owner-Earnings?

As of today (2024-04-25), Kiadis Pharma NV's share price is $6.41. Kiadis Pharma NV does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Kiadis Pharma NV's Price-to-Owner-Earnings or its related term are showing as below:


KIADF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.115
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-25), Kiadis Pharma NV's share price is $6.41. Kiadis Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-2.67. Therefore, Kiadis Pharma NV's PE Ratio for today is At Loss.

As of today (2024-04-25), Kiadis Pharma NV's share price is $6.41. Kiadis Pharma NV's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.67. Therefore, Kiadis Pharma NV's PE Ratio without NRI for today is At Loss.


Kiadis Pharma NV Price-to-Owner-Earnings Historical Data

The historical data trend for Kiadis Pharma NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Price-to-Owner-Earnings Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiadis Pharma NV's Price-to-Owner-Earnings

For the Biotechnology subindustry, Kiadis Pharma NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Price-to-Owner-Earnings falls into.



Kiadis Pharma NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Kiadis Pharma NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.41/-2.39
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (GREY:KIADF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Kiadis Pharma NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (Kiadis Pharma NV) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (Kiadis Pharma NV) Headlines

No Headlines